ChitogenX (TSE:CHGX) has released an update.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
ChitogenX, a clinical-stage regenerative medicine company, has reported a marginal Q1 2025 loss of $0.2 million, a notable improvement from the previous year, alongside positive EBITDA and reduced operational spending. The company is advancing towards commercial readiness, concentrating on securing capital and partnerships for their key programs in burn healing and skin repair. ChitogenX remains committed to reaching its corporate milestones with a strategic focus on non-dilutive and traditional financing.
For further insights into TSE:CHGX stock, check out TipRanks’ Stock Analysis page.